nvp tae266  (MedChemExpress)

Journal: Neuroscience Bulletin

Article Title: Upregulation of NR2A in Glutamatergic VTA Neurons Contributes to Chronic Visceral Pain in Male Mice

doi: 10.1007/s12264-025-01402-7

Figure Lengend Snippet: Increased Glutamate Release and Upregulation of NR2A Expression in the VTA of NMD Mice. A Schematic of glutamate sensor injection and optical fiber implantation in the VTA. B , C Heatmaps and waveform plots of fiber photometry recordings in response to CRD stimulation at 60 mmHg. D Average peak for glutamate signals of glutamatergic VTA neurons while CON and NMD mice receive CRD stimulation (* *P <0.01, two-sample t -test, n = 6 per group). E The area under the curve for glutamate signals of glutamatergic VTA neurons while CON and NMD mice receive CRD stimulation (* *P <0.01, two-sample t -test, n = 6 per group). F mRNA expression levels of NMDARs and the GluR1-4 subunits of AMPARs in the VTA ( **P <0.01, two-sample t -test, n = 4 per group). G The protein patterns of NR2A in the VTA and quantification of changes of NR2A protein expression in the VTA ( *P <0.05, two-sample t -test, n = 4 per group). H Representative images for the co-localization of NR2A (red) and glutamatergic neurons (green) in the VTA of NMD and CON mice (Scale bar, 100 μm). I Percentage of glutamatergic neurons among NR2A + neurons in CON and NMD mice, and the ratio of NR2A + + Glu + / NR2A + in the VTA ( **P <0.01, two-sample t -test, n = 4 sections from 4 mice per group). J The density of glutamatergic neurons and the number of NR2A + neurons in the VTA of CON and NMD groups ( *P <0.05, two-sample t -test, n = 4 sections from 4 mice per group). ns, no significant difference, P >0.05.

Article Snippet: To verify the modulatory effect of NR2A on visceral pain, normal saline (NS) and the NR2A antagonist NVP-AAM077 (MedChemExpress, USA; 1, 10, and 100 μmol/L; 1μL) were microinjected into the VTA of NMD mice via the implanted cannula.

Techniques: Expressing, Injection

Journal: Neuroscience Bulletin

Article Title: Upregulation of NR2A in Glutamatergic VTA Neurons Contributes to Chronic Visceral Pain in Male Mice

doi: 10.1007/s12264-025-01402-7

Figure Lengend Snippet: NR2A contributes to visceral pain via activation of glutamatergic VTA neurons. A Experimental procedure of chemogenetics combined with pharmacology in NMD mice. B Representative EMG traces of pre-NVP-AAM077, post-NVP-AAM077, and NVP-AAM077 + CNO groups. C The area under the curve of EMG at 60 mmHg in NMD mice responding to pre-NVP-AAM077, post-NVP-AAM077, and NVP-AAM077 + CNO groups ( *P <0.05, **P <0.01, two-way ANOVA followed by Sidak’s multiple comparisons test, n = 6 per group). D Schematic of the procedure of chemogenetics combined with pharmacology in CON mice. E Representative EMG traces of pre-CNO, post-CNO, and CNO + NVP-AAM077 groups. F The area under the curve of EMG at 60 mmHg in CON mice responding to pre-CNO, post-CNO, and CNO + NVP-AAM077 groups ( **P <0.01, ***P <0.001, two-way ANOVA followed by Sidak’s multiple comparisons test, n = 6 per group). ns, no significant difference. P >0.05.

Article Snippet: To verify the modulatory effect of NR2A on visceral pain, normal saline (NS) and the NR2A antagonist NVP-AAM077 (MedChemExpress, USA; 1, 10, and 100 μmol/L; 1μL) were microinjected into the VTA of NMD mice via the implanted cannula.

Techniques: Activation Assay

Journal: Neuroscience Bulletin

Article Title: Upregulation of NR2A in Glutamatergic VTA Neurons Contributes to Chronic Visceral Pain in Male Mice

doi: 10.1007/s12264-025-01402-7

Figure Lengend Snippet: Schematic Model: NR2A in Glutamatergic VTA Neurons Regulates Chronic Visceral Pain in Male Mice.

Article Snippet: To verify the modulatory effect of NR2A on visceral pain, normal saline (NS) and the NR2A antagonist NVP-AAM077 (MedChemExpress, USA; 1, 10, and 100 μmol/L; 1μL) were microinjected into the VTA of NMD mice via the implanted cannula.

Techniques:

Journal: Virologica Sinica

Article Title: Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies

doi: 10.1016/j.virs.2025.03.009

Figure Lengend Snippet: Evaluation of antiviral drugs using recombinant HBoV1-HiBiT NS1. A HEK293T cells were transfected with pHBoV1-HiBiT NS1 in the presence of cidofovir (200 ​μM), favipiravir (50 ​μM), ivermectin (10 ​μM), nevirapine (50 ​μM), remdesivir (10 ​μM), ribavirin (50 ​μM), sofosbuvir (50 ​μM), or zidovudin (50 ​μM). At 72 ​h post-transfection, the Nano-Glo luciferase assay was performed. B, C HEK293T cells were transfected with pHBoV1-HiBiT NS1 in the presence of increasing (2-fold) concentrations of ivermectin. At 72 ​h post-transfection, luciferase activity was measured using the Nano-Glo luciferase assay (B) , while the intracellular DNA copy number was quantified by qPCR (C) . The EC50 and CC50 values were determined by fitting the dose-response curves with four-parameter logistic regression in GraphPad Prism. ∗, P ​< ​0.05, ∗∗∗, P ​< ​0.001; ns, not significant.

Article Snippet: The small-molecule compounds cidofovir (#HY-17438), favipiravir (#HY-14768), ivermectin (#HY-15310), nevirapine (#HY-10570), remdesivir (#HY-104077), ribavirin (#HY-B0434), sofosbuvir (#HY-15005), and zidovudine (#HY-17413) were purchased from MCE.

Techniques: Recombinant, Transfection, Luciferase, Activity Assay